Despite barriers of blood, brain and bureaucracy, intranasal insulin may emerge as a promising treatment for pathological memory loss
The newest chemical under investigation for managing Alzheimer’s disease (AD) is actually not new at all. Insulin, the therapeutic hormone all-too familiar to individuals with diabetes, has been around for decades. In fact December will mark 90 years since its discoverers earned the Nobel Prize in Physiology or Medicine for the extraction of insulin for clinical use. Yet to say that insulin has been under our noses all these years wouldn’t exactly be correct. Because if it had been under our noses, we might have sensed its neurologic benefits sooner.
The latest insulin therapy is not delivered via injection like its diabetes-treating counterparts, nor does it come in the form of a pill or a patch like the cholinesterase inhibitors often prescribed to patients with AD. Instead this novel therapeutic enters the body through the nose—the only entry point that gives insulin a chance of reaching the brain.
A large peptide molecule, insulin from the blood cannot float easily into the brain because the blood brain barrier (BBB), a sort of neuroprotective moat, prevents its transport. Fortified by cellular guards called tight junctions, the BBB rejects many pharmacologic hopefuls, allowing entrance only to certain types of substances. Namely small or lipophilic molecules can be administered orally (or via injection, or through the skin) and as long as the relevant chemicals end up in the blood stream, they can casually saunter across the BBB and act on the brain. Large and cumbersome, insulin does not have this luxury and must therefore take a more creative route across the moat.
The nose, conspicuous and sometimes even goofy, provides that creative route. Yet it’s a route that, for many years, researchers were hesitant to take.
“They would say things like, ‘Well, why would there be a blood brain barrier if all you had to do was put something in the nose and it would go to the brain?’” says William H. Frey II, Ph.D., Research Director at HealthPartners Center for Memory & Aging. As of 1989 Frey had been “in the Alzheimer’s deal” for over a decade. At that time he was conducting clinical trials of a neurotrophic factor (a therapeutic protein) to treat AD and, because of the seeming insurmountability of the BBB, the work had been less than fruitful. “It became clear to me that, once again, this neurotrophic factor was not getting effectively into the brain,” he says. So Frey decided to sleep on it. “I went to sleep and I had a dream. And this is how I discovered the intranasal method of getting around the blood brain barrier,” he says. “It had been known since the early 1900s that a number of different viruses that got into the nose would travel up the olfactory nerves and the trigeminal nerves—both of these are nerves that go directly from the nasal mucosa right into the brain. The idea that came to me in this dream in 1989 was: if bad things can do it, why can’t good things do it?”
When Frey revisited the idea upon waking, it registered as simultaneously intuitive and absurd—a logical fantasy like so many dreams.
The Latest Bing News on:
- CPAP, Weight Loss, or Both for Obstructive Sleep Apneaon August 18, 2021 at 5:00 pm
Insulin sensitivity was assessed with the use ... The results of the per-protocol analyses were similar (Figure 3A). Nasal or sinus congestion, nostril irritation, or other upper respiratory ...
- IGF-I Receptor Mutations Resulting in Intrauterine and Postnatal Growth Retardationon August 18, 2021 at 5:00 pm
Phosphorylation of Insulin-like Growth Factor I (IGF-I ... bushy eyebrows, a broad nasal bridge, a broad and rounded nasal tip, a long and smooth philtrum, a thin upper lip, and a broad, everted ...
- Why Some Researchers Are Calling Alzheimer’s Disease a ‘Type 3 Diabetes’on August 17, 2021 at 5:00 pm
Neuron. September 2017. Craft S, Raman R, Chow TW, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia.
- Early Intranasal Insulin Therapy Halts Progression of Neurodegenerationon August 12, 2021 at 5:00 pm
 The subjects were treated with either a placebo, or one of two doses (20–40 IU) of intranasal insulin. At the end of a 4-month protocol, memory and cognitive performance were assessed to ...
- ALTIMMUNE INC (ALT) Q2 2021 Earnings Call Transcripton August 11, 2021 at 5:46 pm
Our encouraging data with our Phase 2 clinical trials with NasoVAX gave us confidence that an intranasal vaccine ... glucose homeostasis, insulin resistance, lipids and inflammatory markers.
- Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2021 Results - Earnings Call Transcripton August 11, 2021 at 1:30 am
Our encouraging data with our Phase 2 clinical trials with NasoVAX gave us confidence that an inter-nasal vaccine could ... glucose homeostasis, insulin resistance, lipids, and inflammatory ...
- Early Intranasal Insulin Therapy Halts Progression of Neurodegenerationon August 7, 2021 at 5:01 pm
The authors' conclusion that individuals in the early stages of AD and those with MCI (pre-AD) might benefit from intranasal insulin therapy is correct and supported by the results. The rationale ...
- Type 1 Diabetes Segment to Dominate the United States Insulin Pumps Market | TechSci Researchon August 7, 2021 at 12:57 am
Insulin pump are medical devices used to administer ... Novolin N), By Route of Administration (Subcutaneous, Transdermal, Nasal, Intravenous, Oral and Others), By Type (Basal, Bolus, Pre-mixed ...
- Evaluate and Track Insulin Companies | View Company Insights for 100+ Insulin Manufacturers and Suppliers | BizVibeon August 6, 2021 at 2:43 pm
NEW YORK, Aug. 6, 2021 /PRNewswire/ -- BizVibe has made available 100+ company profiles for the insulin manufacturers and suppliers category on its B2B platform. Companies listed in this product ...
- Hypoglycemia Treatment Could Be Available For Studentson August 4, 2021 at 9:33 pm
It has the opposite effect of insulin, which lowers blood sugar levels. Injectable glucagon has been approved for use in the U.S. for several decades.The efficacy and safety of Baqsimi nasal powder ...
The Latest Google Headlines on:
The Latest Bing News on:
- Walk to End Alzheimer'son September 2, 2021 at 8:36 pm
Held annually in more than 600 communities nationwide, the Alzheimer's Association Walk to End Alzheimer's is the world's largest fundraiser for Alzheimer's care, support and research. This inspiring ...
- Lawmakers Probe ‘Anomalies’ in Biogen Alzheimer’s Approvalon September 2, 2021 at 5:01 pm
Leaders of two congressional committees probing the approval of Biogen Inc.’s new Alzheimer’s drug pressed the Food and Drug Administration for more information on “apparent anomalies” in the agency’s ...
- House Committees Demand F.D.A. Records on Alzheimer’s Drug Approvalon September 2, 2021 at 11:14 am
The agency approved Biogen’s Aduhelm “despite concerns raised by experts,” committee leaders said in a letter.
- Ex-Finnish president, Nobel winner has advanced Alzheimer’son September 2, 2021 at 8:23 am
Former Finnish President and Nobel Peace Prize winner Martti Ahtisaari is suffering from Alzheimer’s disease and has withdrawn from all public activities. The office of the Finnish President Sauli ...
- Congress Requests Documents From FDA on Approval of Biogen's Alzheimer's Drug - Stat Newson September 2, 2021 at 8:16 am
Two House Committees have requested data and documents from the Food and Drug Administration related to the agency's accelerated approval of Biogen Inc's recently approved Alzheimer’s drug Aduhelm, ...
- U.S. Congress seeks information from FDA on approval of Biogen's Alzheimer's drugon September 2, 2021 at 8:08 am
U.S. lawmakers have requested data and documents from the Food and Drug Administration (FDA) related to its accelerated approval of Biogen Inc's new Alzheimer's drug, mounting further pressure on the ...
- House committees step up investigation into FDA approval of controversial Alzheimer’s drugon September 2, 2021 at 8:00 am
The agency’s accelerated approval of the medication was welcomed by some advocates and doctors as a step forward in treating the devastating disease but strongly criticized by many experts who say the ...
- With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doseson September 1, 2021 at 12:11 pm
A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients.
- Covid could trigger a spike in dementia cases, say Alzheimer's expertson September 1, 2021 at 8:47 am
Research has shown that Covid-19 can increase a person's likelihood of developing dementia, said Alzheimer's Disease International.
- Study finds 'sweet spot' of sleep needed to help prevent Alzheimer's diseaseon September 1, 2021 at 8:26 am
Too much and too little sleep can be bad for your health, research shows. New Stanford University study finds lack of sleep linked to Alzheimer’s disease Sleeping too much or too little each night can ...